Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of Senseonics in a report on Friday, November 15th.

Senseonics Price Performance

NYSE SENS opened at $0.32 on Friday. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The company has a market capitalization of $188.12 million, a price-to-earnings ratio of -2.43 and a beta of 0.79. The stock has a 50-day moving average of $0.34 and a 200 day moving average of $0.39. Senseonics has a one year low of $0.28 and a one year high of $0.75.

Institutional Investors Weigh In On Senseonics

Hedge funds and other institutional investors have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System bought a new stake in Senseonics during the first quarter valued at approximately $91,000. Price T Rowe Associates Inc. MD grew its position in shares of Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after acquiring an additional 51,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Senseonics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after purchasing an additional 155,715 shares in the last quarter. Virtu Financial LLC bought a new position in Senseonics in the 1st quarter worth $162,000. Finally, Cubist Systematic Strategies LLC lifted its position in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares in the last quarter. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.